JP2019512002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512002A5 JP2019512002A5 JP2018539317A JP2018539317A JP2019512002A5 JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153453A JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291143P | 2016-02-04 | 2016-02-04 | |
| US62/291,143 | 2016-02-04 | ||
| PCT/US2017/016407 WO2017136659A2 (en) | 2016-02-04 | 2017-02-03 | Humanized anti-cd3 antibodies, conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Division JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512002A JP2019512002A (ja) | 2019-05-09 |
| JP2019512002A5 true JP2019512002A5 (https=) | 2020-03-26 |
| JP6951826B2 JP6951826B2 (ja) | 2021-10-20 |
Family
ID=59501004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539317A Active JP6951826B2 (ja) | 2016-02-04 | 2017-02-03 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12252534B2 (https=) |
| EP (1) | EP3411069B1 (https=) |
| JP (2) | JP6951826B2 (https=) |
| KR (1) | KR102891788B1 (https=) |
| CN (1) | CN109069635B (https=) |
| AU (1) | AU2017213886B2 (https=) |
| CA (1) | CA3013463C (https=) |
| ES (1) | ES2992761T3 (https=) |
| WO (1) | WO2017136659A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| AU2017213886B2 (en) | 2016-02-04 | 2024-03-07 | The California Institute For Biomedical Research | Humanized anti-CD3 antibodies, conjugates and uses thereof |
| US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| WO2020047176A1 (en) * | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
| CN113490690A (zh) * | 2018-12-29 | 2021-10-08 | 南通壹宸生物医药科技有限公司 | 异源二聚体融合蛋白 |
| CA3131036A1 (en) * | 2019-02-22 | 2020-08-27 | Wuhan Yzy Biopharma Co., Ltd. | Cd3 antigen-binding fragment and application thereof |
| US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| KR20220071263A (ko) * | 2019-09-30 | 2022-05-31 | 하버 바이오메드 (쑤저우) 컴퍼니 리미티드 | Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도 |
| WO2021098834A1 (zh) * | 2019-11-22 | 2021-05-27 | 上海一宸医药科技有限公司 | Psma抗体及其应用 |
| TWI827807B (zh) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | 抗cd3抗體葉酸生物共軛物及其用途 |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| US12195524B2 (en) | 2020-08-25 | 2025-01-14 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| EP4384218A4 (en) * | 2021-08-09 | 2025-11-05 | Merck Patent Gmbh | Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| JP2025540657A (ja) * | 2022-11-18 | 2025-12-16 | ジェイエヌ バイオサイエンシーズ エルエルシー | 抗ｃｄ３抗体 |
| CN120569191A (zh) | 2022-11-23 | 2025-08-29 | 乔治亚大学研究基金公司 | 用于增加免疫应答的组合物及其使用方法 |
| EP4682170A1 (en) * | 2023-03-13 | 2026-01-21 | Mustbio Co., Ltd. | Novel cd3-binding antibody and multispecific antibody comprising same |
| CN121135889A (zh) * | 2024-06-13 | 2025-12-16 | 合肥天港免疫药物有限公司 | 靶向b7h7和cd3的双特异性抗体及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| BR0212897A (pt) | 2001-09-21 | 2004-08-24 | Univ Tulane | Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| SI1629011T1 (sl) | 2003-05-31 | 2010-05-31 | Micromet Ag | Humane molekule za vezavo anti hu cd |
| US8574533B2 (en) | 2004-03-30 | 2013-11-05 | Kureha Corporation | Material for negative electrode of non-aqueous electrolyte secondary battery, process for producing the same, negative electrode and battery |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| AU2006301492B2 (en) * | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| EP1951890A4 (en) | 2005-11-16 | 2009-06-24 | Ambrx Inc | PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS |
| DK1968635T3 (en) | 2005-12-14 | 2014-12-15 | Ambrx Inc | Compositions and Methods of, and uses of non-natural amino acids and polypeptides |
| AU2006332809A1 (en) | 2005-12-30 | 2007-07-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| AU2007215566A1 (en) | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
| EP2079687A1 (en) | 2006-12-18 | 2009-07-22 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2008083346A1 (en) | 2006-12-28 | 2008-07-10 | Ambrx, Inc. | Phenazine and quinoxaline substituted amino acids and polypeptides |
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | CLL-1 ANTIBODY |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| SI2291659T1 (sl) | 2008-05-13 | 2016-02-29 | Yale University | Himerične majhne molekule za pridobivanje protiteles za rakave celice |
| PE20110480A1 (es) | 2008-09-26 | 2011-07-01 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales |
| US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| DK2714733T3 (da) * | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| EP2904016B1 (en) * | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CA2896359A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| TW201446804A (zh) | 2013-05-14 | 2014-12-16 | Ambrx公司 | 新穎多肽小分子結合物及其用途 |
| WO2014195888A1 (en) | 2013-06-07 | 2014-12-11 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| EP3057991B8 (en) * | 2013-10-15 | 2019-09-04 | The Scripps Research Institute | Chimeric antigen receptor t cell switches and uses thereof |
| CN110627907B (zh) | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| UA129760C2 (uk) * | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| JP7020909B2 (ja) * | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| WO2016168773A2 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| AU2017213886B2 (en) | 2016-02-04 | 2024-03-07 | The California Institute For Biomedical Research | Humanized anti-CD3 antibodies, conjugates and uses thereof |
-
2017
- 2017-02-03 AU AU2017213886A patent/AU2017213886B2/en active Active
- 2017-02-03 WO PCT/US2017/016407 patent/WO2017136659A2/en not_active Ceased
- 2017-02-03 US US16/074,600 patent/US12252534B2/en active Active
- 2017-02-03 EP EP17748229.6A patent/EP3411069B1/en active Active
- 2017-02-03 ES ES17748229T patent/ES2992761T3/es active Active
- 2017-02-03 KR KR1020187025472A patent/KR102891788B1/ko active Active
- 2017-02-03 CN CN201780024266.1A patent/CN109069635B/zh active Active
- 2017-02-03 CA CA3013463A patent/CA3013463C/en active Active
- 2017-02-03 JP JP2018539317A patent/JP6951826B2/ja active Active
-
2021
- 2021-09-21 JP JP2021153453A patent/JP2022023052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512002A5 (https=) | ||
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2013530929A5 (https=) | ||
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| FI3596125T3 (fi) | Anti-PAR2-vasta-aineita ja niiden käyttöjä | |
| CY1118008T1 (el) | Πρωτεϊνες δεσμευσης ετεροδιμερους και χρησεις αυτων | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| JP2017518083A (ja) | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 | |
| JP2016538240A5 (https=) | ||
| JP2005120106A5 (https=) | ||
| CN102838663B (zh) | 定点突变和定点修饰的病毒膜蛋白、其制备方法及其应用 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| Okochi et al. | Array-based rational design of short peptide probe-derived from an anti-TNT monoclonal antibody | |
| NZ598770A (en) | Monoclonal antibodies | |
| JP2013538791A5 (https=) | ||
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| WO2019104155A3 (en) | Chemical probe-dependent evaluation of protein activity and uses thereof | |
| RU2015154792A (ru) | Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus |